
An Ohio couple welcomes a baby boy from a nearly 31-year-old frozen embryo
A baby boy born last week to an Ohio couple developed from an embryo that had been frozen for more than 30 years in what is believed to be a record length of storage time before a birth.
In what's known as embryo adoption, Linda and Tim Pierce used a handful of embryos donated in 1994 in their pursuit of having a child after fighting infertility for years. Their son was born Saturday from an embryo that had been in storage for 11,148 days, which the Pierces' doctor says sets a record.
It's a concept that has been around since the 1990s but is gaining attraction as some fertility clinics and advocates, often Christian-centered, oppose discarding leftover embryos because of their belief that life begins at or around conception and that all embryos deserve to be treated like children who need a home.
'I felt all along that these three little hopes, these little embryos, deserved to live just like my daughter did,' said Linda Archerd, 62, who donated her embryos to the Pierces.
Just about two per cent of births in the U.S. are the result of in vitro fertilization, and an even smaller fraction involve donated embryos.
However, medical experts estimate about 1.5 million frozen embryos are currently being stored throughout the country, with many of those in limbo as parents wrestle with what to do with their leftover embryos created in IVF labs.
Further complicating the topic is a 2024 Alabama Supreme Court decision that said that frozen embryos have the legal status of children. State leaders have since devised a temporary solution shielding clinics from liability stemming from that ruling, though questions linger about remaining embryos.
Archerd says she turned to IVF in 1994. Back then, the ability to freeze, thaw and transfer embryos was making key progress and opening the door for hopeful parents to create more embryos and increase their chances of a successful transfer.
She wound up with four embryos and initially hoped to use them all. But after the birth of her daughter, Archerd and her husband divorced, disrupting her timeline for having more children.
As the years turned into decades, Archerd said she was wracked with guilt about what to do with the embryos as storage fees continued to rise.
Eventually, she found Snowflakes, a division of Nightlight Christian Adoptions, which offers open adoptions to donors. Archerd was also able to set preferences for what families would adopt her embryos.
'I wanted to be a part of this baby's life,' she said. 'And I wanted to know the adopting parents.'
The process was tricky, requiring Archerd to contact her initial fertility doctor in Oregon and dig through paper records to get the proper documentation for the donation. The embryos then had to be shipped from Oregon to the Pierces' doctor in Tennessee. The clinic, Rejoice Fertility in Knoxville, refuses to discard frozen embryos and has become known for handling embryos stored in outdated and older containers.
Of the three donated embryos the Pierces received from Archerd, one didn't make the thaw. Two were transferred to Lindsey Pierce's womb, but just one successfully implanted.
According to Dr. John David Gordon, the transfer of the nearly 31-year-old embryo marks the longest-frozen embryo to result in a live birth. He would know, Gordon says his clinic assisted in the previous record, when Lydia and Timothy Ridgeway were born from embryos frozen for 30 years, or 10,905 days.
'I think that these stories catch the imagination,' Gordon said. 'But I think they also provide a little bit of a cautionary tale to say: Why are these embryos sitting in storage? You know, why do we have this problem?'
In a statement, Lindsey and Tim Pierce said the clinic's support was just what they needed.
'We didn't go into this thinking about records — we just wanted to have a baby,' Lindsey Pierce said.
For Archerd, the donation process has been an emotional roller coaster. Relief that her embryos finally found a home, sadness it couldn't be with her and a little anxiety about what the future holds next, with possibly meeting the Pierces and the baby in person.
'I'm hoping that they're going to send pictures,' she said, noting that the parents have already sent several after the birth. 'I'd love to meet them some day. That would be a dream come true to meet — meet them and the baby.'
Kimberlee Kruesi, The Associated Press
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBC
24 minutes ago
- CBC
Expert discusses potential impact of Trump's demand to slash drug prices in U.S.
U.S. President Donald Trump has issued a direct warning to top pharmaceutical companies, demanding they slash drug prices. Mina Tadrous, an associate professor at the University of Toronto's Leslie Dan Faculty of Pharmacy, discusses concerns and how this could impact drug prices in Canada.


Globe and Mail
2 hours ago
- Globe and Mail
AstraZeneca's AZD3427 Study: A Potential Game-Changer for Heart Failure and Pulmonary Hypertension
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase IIb study titled A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2). The study aims to assess the efficacy of AZD3427 in reducing pulmonary vascular resistance in patients with heart failure and pulmonary hypertension over 24 weeks, highlighting its potential significance in treating these conditions. The intervention being tested is AZD3427, administered as a subcutaneous injection. It is designed to target pulmonary hypertension by reducing vascular resistance, with the study evaluating three different dose levels of the drug. The study follows a randomized, parallel assignment model with triple masking, involving participants, care providers, and investigators. Its primary purpose is treatment-focused, aiming to determine the optimal dosing strategy for AZD3427. The study began on April 24, 2023, with an estimated completion date in July 2025. These timelines are crucial for tracking the progress and potential market introduction of AZD3427. The outcome of this study could significantly impact AstraZeneca's market position, potentially boosting its stock performance if results are positive. Investors will be keenly watching for updates, especially in the context of competitive treatments for heart failure and pulmonary hypertension. The study is ongoing, with further details available on the ClinicalTrials portal.


CTV News
5 hours ago
- CTV News
Canada has its 1st case of West Nile this year. Here's what to know about the virus
TORONTO — Confirmation of the first human case of West Nile virus acquired in Canada this year arrived just in time for the August long weekend. The Public Health Agency of Canada said Thursday that an adult in Toronto with no travel history has been infected with the mosquito-borne virus. There had previously been two people with West Nile virus in Canada, but they were infected while travelling outside the country. Here's what you need to know about West Nile virus as you head outdoors this weekend. What is West Nile virus? The first human case of West Nile virus appeared in Canada in 2002. The virus was originally identified in the West Nile region of Uganda, said Dr. Isaac Bogoch, an infectious diseases specialist at the University Health Network in Toronto, but was carried to many places around the world by migratory birds. When mosquitoes bite infected birds, they in turn become infected and then can pass on the virus to humans and other animals when they bite them. The type of mosquitoes that transmit West Nile virus usually bite around dusk and at night, Bogoch said. Human infections usually occur in mid to late summer, petering out as the temperature cools down. The Public Health Agency of Canada says humans don't spread the virus to other humans, except for very rare cases including blood transfusions, organ or tissue transplants, mother-to-child transmission during pregnancy or breastfeeding. What are the symptoms? 'The vast majority of people who are bitten by a mosquito harbouring West Nile virus will have no symptoms whatsoever,' said Bogoch. For the 20 to 30 per cent of people who get sick, most will have a few days of symptoms that resolve on their own. Symptoms usually begin between two and 14 days after the mosquito bite. They can include fever, muscle aches, headaches, fatigue, nausea, vomiting, skin rash, swollen lymph glands and a stiff neck. The concerning part of West Nile virus is that up to two per cent of people infected will get neuroinvasive disease, including encephalitis or meningitis, Bogoch said. Encephalitis is inflammation of the brain and meningitis is inflammation of the area around the brain and spinal cord. In 'very rare' cases, people can also develop paralysis, he said. Although anyone can get these severe West Nile virus infections, they tend to happen more in older adults, Bogoch said. How is West Nile virus treated? There is no antiviral medication to treat West Nile virus. Most people won't need medical attention and can manage aches and pains with over-the-counter acetaminophen, rest and fluids. For the rare cases of neuroinvasive diseases, hospitals provide supportive care, including fluids and electrolytes, and provide rehabilitation if needed. Is there a vaccine for West Nile virus? There is no vaccine for West Nile virus. How can I prevent West Nile virus? The best way to prevent West Nile virus is to avoid being bitten by a mosquito in the first place. Using insect repellent is 'very effective,' Bogoch said. Both Bogoch and the Public Health Agency of Canada recommend using bug sprays and lotions containing the chemicals DEET or Icaridine. Health Canada says those products should not be used on infants under six months old and parents can use mosquito nets over cribs or strollers when babies are outside instead. Wearing long sleeves and long pants, socks and a hat can also protect against mosquito bites. People can also wear mosquito nets over their hats. Choose light-coloured clothing, because mosquitoes are attracted to dark colours. Making sure all open windows have screens to keep mosquitoes and other bugs out is important. Getting rid of any standing water around your home or cottage also helps because that's where mosquitoes lay eggs. Drain buckets, planters, old tires, pool covers, wading pools and other objects where water accumulates. How common is it? The number of reported cases annually varies greatly since PHAC started tracking domestic infections in 2003, ranging from a handful of cases per year to a peak of 2,401 cases in 2007. In 2024, there were 166 reported cases, according to PHAC's preliminary data. 'For most Canadians, the risk of getting infected is low because relatively few mosquitoes in Canada are infected with West Nile virus,' said Mark Johnson, a spokesperson for PHAC, in an email Friday. This report by The Canadian Press was first published Aug. 2, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content. Nicole Ireland, The Canadian Press